These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18695885)

  • 1. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
    Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
    Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
    Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
    Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
    Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD5+ T-cell/histiocyte-rich large B-cell lymphoma.
    Chang CC; Bunyi-Teopengco E; Eshoa C; Chitambar CR; Kampalath B
    Mod Pathol; 2002 Oct; 15(10):1051-7. PubMed ID: 12379751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
    Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
    Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
    Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
    Morley AM; Verity DH; Meligonis G; Rose GE
    Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
    Ho CH; Chen CL; Li WY; Chen CJ
    Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.
    Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y
    Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
    Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
    Lin WW; Hsieh SL
    Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
    Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased FHIT protein expression correlates with a worse prognosis in patients with diffuse large B-cell lymphoma.
    Chen PM; Yang MH; Hsiao LT; Yu IT; Chu CJ; Chao TC; Yen CC; Wang WS; Chiou TJ; Liu JH
    Oncol Rep; 2004 Feb; 11(2):349-56. PubMed ID: 14719066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development.
    Chen C; Zhang C; Zhuang G; Luo H; Su J; Yin P; Wang J
    Cancer Invest; 2008 Dec; 26(10):965-74. PubMed ID: 19093253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.